In:
Pharmacology, S. Karger AG, Vol. 99, No. 1-2 ( 2017), p. 84-88
Abstract:
〈 b 〉 〈 i 〉 Background/Aims: 〈 /i 〉 〈 /b 〉 Attention deficit hyperactivity disorder (ADHD) is frequently associated with other psychiatric pathologies. Therefore, the present study investigated a possible pharmacokinetic interaction between atomoxetine (ATX), a treatment option for ADHD, and an antidepressant, namely, fluvoxamine (FVX). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Designed as an open-label, non-randomized clinical trial, the study included 2 periods. In period 1 (reference), each subject received ATX 25 mg (single-dose), whereas in period 2 (test), all subjects were given a combination of ATX 25 mg + FVX 100 mg, following a 6-day pretreatment regimen with the enzymatic inhibitor. Non-compartmental methods were employed to determine the pharmacokinetic parameters of ATX and its main active metabolite (glucuronidated form), 4-hydroxyatomoxetine- 〈 i 〉 O 〈 /i 〉 -glucuronide. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The results revealed significant differences between the study periods for C 〈 sub 〉 max 〈 /sub 〉 , AUC 〈 sub 〉 0-t 〈 /sub 〉 and AUC 〈 sub 〉 0- 〈 /sub 〉 〈 sub 〉 ∞ 〈 /sub 〉 values corresponding to ATX and its metabolite. Small, but statistically significant increases in AUC values were reported for both parent drug (1,583.05 ± 1,040.29 vs. 2,111.55 ± 1,411.59 ng*h/ml) and 4-hydroxyatomoxetine- 〈 i 〉 O 〈 /i 〉 -glucuronide (5,754.71 ± 1,235.5 vs. 6,293.17 ± 1,219.34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 FVX had a modest effect on the pharmacokinetics of ATX and 4-hydroxyatomoxetine- 〈 i 〉 O 〈 /i 〉 -glucuronide. The presence or absence of any clinical consequences associated with this pharmacokinetic drug-drug interaction needs to be established in future studies.
Type of Medium:
Online Resource
ISSN:
0031-7012
,
1423-0313
Language:
English
Publisher:
S. Karger AG
Publication Date:
2017
detail.hit.zdb_id:
1483550-2
SSG:
15,3
Permalink
